Mark Richards, MD
Family Medicine · Charleston, WVNPI 1285895938
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,603 of the $10,015 with a category attached, or 65.9%. 41 manufacturers reported payments, led by Abbott at 36.5% of the total. Reporting peaked in 2021 at $4,581 and has fallen 73.4% since, to $1,218 in 2025. Among family medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Pfizer$1K
- Novo Nordisk$1K
- AbbVie$529
- Novartis$519
- AstraZeneca$463
- plus $3K from 35 others
What the payments were for
- Consulting fees$3,41334%
- Food & beverage$6,60366%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,015 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $84,404 |
| OzempicSemaglutide | 47 | $63,101 |
| EliquisApixaban | 49 | $60,346 |
| JanuviaSitagliptin Phosphate | 34 | $45,546 |
| JardianceEmpagliflozin | 28 | $44,620 |
| TrulicityDulaglutide | 17 | $35,177 |
| EntrestoSacubitril/Valsartan | 18 | $31,629 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $29,367 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $27,248 |
| Spiriva RespimatTiotropium Bromide | 12 | $17,145 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $16,850 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $6,811 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $5,800 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,594 |
| Potassium Chloride | 90 | $5,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,115 | $63,10147 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $115 | $61,76540 claims |
| PfizerEliquis | $1,198 | $60,34649 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $423 | $51,81158 claims |
| MerckJanuvia | $147 | $45,54634 claims |
| Lilly USA, LLCTrulicity | $223 | $35,17717 claims |
| NovartisEntresto | $519 | $31,62918 claims |
| AstraZenecaSymbicort | $463 | $6,81116 claims |
| AbbVieSynthroid | $529 | $2,25728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Charleston
- Melissa GamponiaCharleston$18K
- Donald MooreCharleston$17K
- John LewisCharleston$11K
- Jennifer LaddCharleston$7K
- Julie DetempleSouth Charleston$129K
- John CornellHuntington$68K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
- David HessBridgeport$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.